Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects

Seoul National University

Status and phase: Unknown; Phase 4

Conditions: Healthy; Chronic Constipation; Constipated Irritable Bowel Syndrome

Treatments: Drug: Mosapride

Study type: Interventional

Funder types: Other

Identifiers

NCT02433847

Mosa_GIFx_1.0

Details and patient eligibility

About

Effect of mosapride 30mg/day on the small bowel and colon transit time in patients with chronic constipation or constipated irritable bowel syndrome.

Enrollment: 20 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Functional constipation or constipated irritable bowel syndrome patients according to Rome III criteria

Exclusion criteria

• Intolerable or hypersensitive to mosapride
• Known Parkinson's ds
• Cardio- or cerebrovascular disease within 3 months
• Malignancy requiring surgery or chemotherapy or radiation within 5 years
• History of GI surgeries except hernia repair, appendectomy, primary closure due to perforation
• Refractory diabetes mellitus/hypertension/thyroid diseases
• Symptomatic heart failure, renal failure, arrhythmia

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

mosapride

Experimental group

Treatment:

Drug: Mosapride